Anne Calkins, MD
Emergency Medicine · North Syracuse, NYNPI 1023035706
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $51,319 of the $64,867 with a category attached, or 79.1%. CSL Plasma Inc. accounts for 79.1% of it on its own, with 24 other manufacturers making up the rest. Among emergency medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $381.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$51K
- AbbVie$11K
- Medtronic$466
- Johnson & Johnson$449
- Collegium Pharmaceutical, Inc.$236
- SPR Therapeutics, Inc$153
- plus $1K from 19 others
What the payments were for
- Consulting fees$51,31979%
- Speaking & faculty fees$10,70016%
- Food & beverage$2,8134%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 66 | $51,319 |
| AbbVie(2 entities) | 12 | $11,013 |
| Medtronic(2 entities) | 8 | $466 |
| Johnson & Johnson | 11 | $449 |
| Collegium Pharmaceutical, Inc. | 16 | $236 |
| SPR Therapeutics, Inc | 2 | $153 |
| Abbott | 3 | $152 |
| Vertex | 6 | $126 |
| Axsome Therapeutics, Inc. | 1 | $121 |
| Si-bone, Inc. | 5 | $115 |
| Amgen(2 entities) | 5 | $108 |
| Teva Pharmaceuticals USA, Inc. | 7 | $107 |
| Averitas Pharma Inc. | 4 | $94 |
| GRT US Holding, Inc. | 3 | $72 |
| Scilex Pharmaceuticals Inc. | 4 | $56 |
| Nevro Corp. | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $50 |
| Pfizer | 2 | $32 |
| Boston Scientific | 2 | $30 |
| Daiichi Sankyo Inc. | 2 | $29 |
| Novo Nordisk | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| DJO, LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$10,800
- SPRAVATO$240
- INTELLIS ADAPTIVESTIM$124
- Auvelity$121
- PROCLAIM$116
How this compares
$64,867 in reported general payments places this provider in the 95th percentile of 4,167 emergency medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levorphanol Tartrate | 39 | $147,918 |
| OxycontinOxycodone Hcl | 65 | $91,727 |
| Xtampza ErOxycodone Myristate | 99 | $56,658 |
| BelbucaBuprenorphine Hcl | 72 | $51,922 |
| Nucynta ErTapentadol Hcl | 42 | $49,536 |
| Buprenorphine | 125 | $36,566 |
| Nurtec OdtRimegepant Sulfate | 22 | $33,945 |
| NucyntaTapentadol Hcl | 42 | $31,969 |
| CreonLipase/Protease/Amylase | 11 | $14,707 |
| SymproicNaldemedine Tosylate | 27 | $14,440 |
| ButransBuprenorphine | 24 | $13,840 |
| Hysingla ErHydrocodone Bitartrate | 26 | $10,708 |
| SavellaMilnacipran Hcl | 21 | $10,275 |
| MovantikNaloxegol Oxalate | 24 | $9,154 |
| Dronabinol | 26 | $8,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er, Nucynta | $236 | $190,085255 claims |
| PfizerNurtec Odt | $32 | $33,94522 claims |
| AbbVieCreon, Savella | $11,013 | $24,98232 claims |
| Shionogi IncSymproic | $12 | $14,44027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,167 emergency medicine providers in New York.
Other emergency medicine in North Syracuse
- David JanickeWilliamsville$441K
- Joseph BartBuffalo$315K
- Joseph HabbousheNew York$309K
- Adam SingerStony Brook$297K
- Sohan ParekhNew York$174K
- Benjamin AbellaNew York$143K
- David LevineCorning$138K
- Harry KopolovichBronx$131K
- Christopher RaioManhasset$92K
- Robert BiernbaumFairport$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.